← SynDRA
AMG-900
SynDRA canonical compound SYN0033797 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | AURKA | AURKB | AURKC |
|---|
| Mechanism of action | Aurora kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- AURKB INHIBITOR
- Serine/threonine-protein kinase Aurora inhibitor
- AURKC INHIBITOR
- AURKA INHIBITOR
- aurora kinase inhibitor
- AURKC MODULATOR
- AURKB MODULATOR
- AURKA MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- YJ005
- STK26
- CDK12
- CDK13
- RPS6KA5
- RPS6KA4
- CLK1
- CLK2
- CLK3
- RET
- DDR1
- DDR2
- PRKD3
- PRKD2
- PRKCD
- FES
- NQO2
- NEK1
- MAP2K1
- MAP2K2
- MAPKAPK2
- MAP3K2
- MAP3K3
- ABL1
- MAP3K5
- MAP4K2
- MAP4K5
- CAMK4
- MAPK14
- ULK1
- BRAF
- TAOK1
- THRAP3
- TOP2B
- TAOK3
- BCR
- SYK
- PAICS
- OPA1
- OLA1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ATXN2
- CP2C9
- CP3A7
- IFNG
- NSD2
Cross-references
Synonyms
- AMG 900
- AMG 18 HYDROCHLORIDE
- AMG900
- UNII-9R2G075611
- N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen- 2-yl)phthalazin-1-amine
- 9R2G075611
- N-(4-((3-(2-aminopyrimidin-4-yl)pyridin-2-yl)oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine
- N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine
- IVUGFMLRJOCGAS-UHFFFAOYSA-N
- N-(4-((3-(2-aminopyrimidin-4-yl)pyridin-2-yl)oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine.
- ZINC43208325
- MLS006011192
- SCHEMBL503564
- GTPL8060
- AMG 900 [WHO-DD]
- CHEMBL2140408
- DTXSID90241526
- HMS3656H17
- BCP02552
- EX-A1793
- BDBM50466803
- NSC761069
- NSC799331
- s2719
- AKOS027276402
- BCP9000292
- CCG-264985
- CS-0485
- NSC-761069
- NSC-799331
- SB16661
- NCGC00263094-01
- NCGC00263094-06
- AC-35905
- BS-17914
- HY-13253
- N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine
- SMR004702961
- SW219731-1
Look up AMG-900 in the interactive SynDRA portal →